Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

Robert A. Seder, Lee Jah Chang, Mary E. Enama, Kathryn L. Zephir, Uzma N. Sarwar, Ingelise J. Gordon, LaSonji A. Holman, Eric R. James, Peter F. Billingsley, Anusha Gunasekera, Adam Richman, Sumana Chakravarty, Anita Manoj, Soundarapandian Velmurugan, MingLin Li, Adam J. Ruben, Tao Li, Abraham G. Eappen, Richard E. Stafford, Sarah H. PlummerCynthia S. Hendel, Laura Novik, Pamela J M Costner, Floreliz H. Mendoza, Jamie G. Saunders, Martha C. Nason, Jason H. Richardson, Jittawadee Murphy, Silas A. Davidson, Thomas L. Richie, Martha Sedegah, Awalludin Sutamihardja, Gary A. Fahle, Kirsten E. Lyke, Matthew B. Laurens, Mario Roederer, Kavita Tewari, Judith E. Epstein, B. Kim Lee Sim, Julie E. Ledgerwood, Barney S. Graham, Stephen L. Hoffman

Research output: Contribution to journalArticle

396 Citations (Scopus)

Abstract

Consistent, high-level, vaccine-induced protection against human malaria has only been achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites. We report that the PfSPZ Vaccine - composed of attenuated, aseptic, purified, cryopreserved PfSPZ - was safe and well tolerated when administered four to six times intravenously (IV) to 40 adults. Zero of six subjects receiving five doses and three of nine subjects receiving four doses of 1.35 × 105 PfSPZ Vaccine and five of six nonvaccinated controls developed malaria after controlled human malaria infection (P = 0.015 in the five-dose group and P = 0.028 for overall, both versus controls). PfSPZ-specific antibody and T cell responses were dose-dependent. These data indicate that there is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards.

Original languageEnglish (US)
Pages (from-to)1359-1365
Number of pages7
JournalScience
Volume341
Issue number6152
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Sporozoites
Malaria
Immunization
Vaccines
Attenuated Vaccines
Bites and Stings
Plasmodium falciparum
Culicidae
T-Lymphocytes
Antibodies
Infection

ASJC Scopus subject areas

  • General

Cite this

Seder, R. A., Chang, L. J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., ... Hoffman, S. L. (2013). Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science, 341(6152), 1359-1365. https://doi.org/10.1126/science.1241800

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. / Seder, Robert A.; Chang, Lee Jah; Enama, Mary E.; Zephir, Kathryn L.; Sarwar, Uzma N.; Gordon, Ingelise J.; Holman, LaSonji A.; James, Eric R.; Billingsley, Peter F.; Gunasekera, Anusha; Richman, Adam; Chakravarty, Sumana; Manoj, Anita; Velmurugan, Soundarapandian; Li, MingLin; Ruben, Adam J.; Li, Tao; Eappen, Abraham G.; Stafford, Richard E.; Plummer, Sarah H.; Hendel, Cynthia S.; Novik, Laura; Costner, Pamela J M; Mendoza, Floreliz H.; Saunders, Jamie G.; Nason, Martha C.; Richardson, Jason H.; Murphy, Jittawadee; Davidson, Silas A.; Richie, Thomas L.; Sedegah, Martha; Sutamihardja, Awalludin; Fahle, Gary A.; Lyke, Kirsten E.; Laurens, Matthew B.; Roederer, Mario; Tewari, Kavita; Epstein, Judith E.; Sim, B. Kim Lee; Ledgerwood, Julie E.; Graham, Barney S.; Hoffman, Stephen L.

In: Science, Vol. 341, No. 6152, 2013, p. 1359-1365.

Research output: Contribution to journalArticle

Seder, RA, Chang, LJ, Enama, ME, Zephir, KL, Sarwar, UN, Gordon, IJ, Holman, LA, James, ER, Billingsley, PF, Gunasekera, A, Richman, A, Chakravarty, S, Manoj, A, Velmurugan, S, Li, M, Ruben, AJ, Li, T, Eappen, AG, Stafford, RE, Plummer, SH, Hendel, CS, Novik, L, Costner, PJM, Mendoza, FH, Saunders, JG, Nason, MC, Richardson, JH, Murphy, J, Davidson, SA, Richie, TL, Sedegah, M, Sutamihardja, A, Fahle, GA, Lyke, KE, Laurens, MB, Roederer, M, Tewari, K, Epstein, JE, Sim, BKL, Ledgerwood, JE, Graham, BS & Hoffman, SL 2013, 'Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine', Science, vol. 341, no. 6152, pp. 1359-1365. https://doi.org/10.1126/science.1241800
Seder, Robert A. ; Chang, Lee Jah ; Enama, Mary E. ; Zephir, Kathryn L. ; Sarwar, Uzma N. ; Gordon, Ingelise J. ; Holman, LaSonji A. ; James, Eric R. ; Billingsley, Peter F. ; Gunasekera, Anusha ; Richman, Adam ; Chakravarty, Sumana ; Manoj, Anita ; Velmurugan, Soundarapandian ; Li, MingLin ; Ruben, Adam J. ; Li, Tao ; Eappen, Abraham G. ; Stafford, Richard E. ; Plummer, Sarah H. ; Hendel, Cynthia S. ; Novik, Laura ; Costner, Pamela J M ; Mendoza, Floreliz H. ; Saunders, Jamie G. ; Nason, Martha C. ; Richardson, Jason H. ; Murphy, Jittawadee ; Davidson, Silas A. ; Richie, Thomas L. ; Sedegah, Martha ; Sutamihardja, Awalludin ; Fahle, Gary A. ; Lyke, Kirsten E. ; Laurens, Matthew B. ; Roederer, Mario ; Tewari, Kavita ; Epstein, Judith E. ; Sim, B. Kim Lee ; Ledgerwood, Julie E. ; Graham, Barney S. ; Hoffman, Stephen L. / Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. In: Science. 2013 ; Vol. 341, No. 6152. pp. 1359-1365.
@article{7c19af6bd4084ce0a64bda97a14cd43a,
title = "Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine",
abstract = "Consistent, high-level, vaccine-induced protection against human malaria has only been achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites. We report that the PfSPZ Vaccine - composed of attenuated, aseptic, purified, cryopreserved PfSPZ - was safe and well tolerated when administered four to six times intravenously (IV) to 40 adults. Zero of six subjects receiving five doses and three of nine subjects receiving four doses of 1.35 × 105 PfSPZ Vaccine and five of six nonvaccinated controls developed malaria after controlled human malaria infection (P = 0.015 in the five-dose group and P = 0.028 for overall, both versus controls). PfSPZ-specific antibody and T cell responses were dose-dependent. These data indicate that there is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards.",
author = "Seder, {Robert A.} and Chang, {Lee Jah} and Enama, {Mary E.} and Zephir, {Kathryn L.} and Sarwar, {Uzma N.} and Gordon, {Ingelise J.} and Holman, {LaSonji A.} and James, {Eric R.} and Billingsley, {Peter F.} and Anusha Gunasekera and Adam Richman and Sumana Chakravarty and Anita Manoj and Soundarapandian Velmurugan and MingLin Li and Ruben, {Adam J.} and Tao Li and Eappen, {Abraham G.} and Stafford, {Richard E.} and Plummer, {Sarah H.} and Hendel, {Cynthia S.} and Laura Novik and Costner, {Pamela J M} and Mendoza, {Floreliz H.} and Saunders, {Jamie G.} and Nason, {Martha C.} and Richardson, {Jason H.} and Jittawadee Murphy and Davidson, {Silas A.} and Richie, {Thomas L.} and Martha Sedegah and Awalludin Sutamihardja and Fahle, {Gary A.} and Lyke, {Kirsten E.} and Laurens, {Matthew B.} and Mario Roederer and Kavita Tewari and Epstein, {Judith E.} and Sim, {B. Kim Lee} and Ledgerwood, {Julie E.} and Graham, {Barney S.} and Hoffman, {Stephen L.}",
year = "2013",
doi = "10.1126/science.1241800",
language = "English (US)",
volume = "341",
pages = "1359--1365",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6152",

}

TY - JOUR

T1 - Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

AU - Seder, Robert A.

AU - Chang, Lee Jah

AU - Enama, Mary E.

AU - Zephir, Kathryn L.

AU - Sarwar, Uzma N.

AU - Gordon, Ingelise J.

AU - Holman, LaSonji A.

AU - James, Eric R.

AU - Billingsley, Peter F.

AU - Gunasekera, Anusha

AU - Richman, Adam

AU - Chakravarty, Sumana

AU - Manoj, Anita

AU - Velmurugan, Soundarapandian

AU - Li, MingLin

AU - Ruben, Adam J.

AU - Li, Tao

AU - Eappen, Abraham G.

AU - Stafford, Richard E.

AU - Plummer, Sarah H.

AU - Hendel, Cynthia S.

AU - Novik, Laura

AU - Costner, Pamela J M

AU - Mendoza, Floreliz H.

AU - Saunders, Jamie G.

AU - Nason, Martha C.

AU - Richardson, Jason H.

AU - Murphy, Jittawadee

AU - Davidson, Silas A.

AU - Richie, Thomas L.

AU - Sedegah, Martha

AU - Sutamihardja, Awalludin

AU - Fahle, Gary A.

AU - Lyke, Kirsten E.

AU - Laurens, Matthew B.

AU - Roederer, Mario

AU - Tewari, Kavita

AU - Epstein, Judith E.

AU - Sim, B. Kim Lee

AU - Ledgerwood, Julie E.

AU - Graham, Barney S.

AU - Hoffman, Stephen L.

PY - 2013

Y1 - 2013

N2 - Consistent, high-level, vaccine-induced protection against human malaria has only been achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites. We report that the PfSPZ Vaccine - composed of attenuated, aseptic, purified, cryopreserved PfSPZ - was safe and well tolerated when administered four to six times intravenously (IV) to 40 adults. Zero of six subjects receiving five doses and three of nine subjects receiving four doses of 1.35 × 105 PfSPZ Vaccine and five of six nonvaccinated controls developed malaria after controlled human malaria infection (P = 0.015 in the five-dose group and P = 0.028 for overall, both versus controls). PfSPZ-specific antibody and T cell responses were dose-dependent. These data indicate that there is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards.

AB - Consistent, high-level, vaccine-induced protection against human malaria has only been achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites. We report that the PfSPZ Vaccine - composed of attenuated, aseptic, purified, cryopreserved PfSPZ - was safe and well tolerated when administered four to six times intravenously (IV) to 40 adults. Zero of six subjects receiving five doses and three of nine subjects receiving four doses of 1.35 × 105 PfSPZ Vaccine and five of six nonvaccinated controls developed malaria after controlled human malaria infection (P = 0.015 in the five-dose group and P = 0.028 for overall, both versus controls). PfSPZ-specific antibody and T cell responses were dose-dependent. These data indicate that there is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards.

UR - http://www.scopus.com/inward/record.url?scp=84884671436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884671436&partnerID=8YFLogxK

U2 - 10.1126/science.1241800

DO - 10.1126/science.1241800

M3 - Article

C2 - 23929949

AN - SCOPUS:84884671436

VL - 341

SP - 1359

EP - 1365

JO - Science

JF - Science

SN - 0036-8075

IS - 6152

ER -